Drug Trial Radar · NCT07483554
IBI343 in Combination Therapy for Advanced Malignant Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jun 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
389
Planned (sponsor's estimate)
Start
Apr 20, 2026
Primary completion
Mar 31, 2028
Study completion Mar 31, 2028
Sponsor
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 19, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase II study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of IBI343 in combination therapy for patients with advanced malignant solid tumors.To evaluate the efficacy and safety of IBI343 in combination therapy for patients with advanced malignant solid tumors.Enrollment of subjects with advanced gastric/gastroesophageal junction adenocarcinoma positive for CLDN18.2, and subjects with pancreatic ductal adenocarcinoma positive for CLDN18.2.
Conditions
- CLDN18.2 Positive
- Gastric/Gastroesophageal Junction Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma
Interventions
IBI343,Gemcitabine, Albumin-bound PaclitaxelDrug
IBI343,Gemcitabine, Albumin-bound Paclitaxel intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) evaluated according to RECIST v1.1Time frame: Up to 24 months
- Incidence of Adverse Events (AE)Time frame: Up to 24 months
- Incidence of treatment-emergent adverse Events (TEAE)Time frame: Up to 24 months
- Incidence of adverse events of Special Interest (AESI)Time frame: Up to 24 months
- Incidence of serious adverse events (SAE)Time frame: Up to 24 months
- Number of participants with abnormal laboratory tests resultsTime frame: Up to 24 months
- Number of subjects with clinically significant changes in physical examination resultsTime frame: Up to 24 months
- Number of subjects with clinically significant changes in vital signsTime frame: Up to 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.